Related Experiment Video
Updated: Nov 2, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Anticoagulation in COVID-19: reaction to the ACTION trial
Jeffrey S Berger1, Jean Marie Connors2
1Center for the Prevention of Cardiovascular Disease, New York University School of Medicine, New York, NY 10016, USA; New York University Langone Health, New York, NY, USA.
No abstract available in PubMed .
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

